The pharmacokinetics (PKs) and safety of medications in particular groups can be predicted
using the physiologically‐based pharmacokinetic (PBPK) model. Using the PBPK model …

Introduction Physiologically based pharmacokinetic (PBPK) modeling is a paradigm shift in
this era for determining the exposure of drugs in pediatrics, geriatrics, and patients with …

Over the last several decades, angiotensin-converting enzyme inhibitors (ACEIs) have been
a staple in the treatment of hypertension and renovascular disorders in children. One of the …

Pregabalin (PGB) is widely used clinically; however, its pharmacokinetics (PK) has not been
studied in pediatric patients with renal impairment (RI). To design optimized PGB regimens …

Abstract Background and Objective Chronic kidney disease (CKD) may alter drug renal
elimination but is also known for interacting with hepatic metabolism via multiple uremic …

Background Cefotaxime is commonly used in treating bacterial infections in neonates. To
characterize the pharmacokinetic process in neonates and evaluate different recommended …

The pharmacokinetics of teicoplanin differs in children as compared with adults, and
especially in renally impaired pediatric patients. Inappropriate empirical antibacterial …

Dose recommendations for lamivudine or emtricitabine in children with HIV and chronic
kidney disease (CKD) are absent or not supported by clinical data. Physiologically based …

Ceftazidime is a third-generation cephalosporin with high activity against many pathogens.
But the ambiguity and diversity of the dosing regimens in neonates and young infants impair …

Ceftaroline fosamil is a fifth‐generation cephalosporin approved as a treatment for adults
and children with community‐acquired bacterial pneumonia and acute bacterial skin and …